Summary
Unable to evaluate alignment because the AI response text provided does not match the labeled product and formulation: the label supplied is for INQOVI (decitabine/cedazuridine) while the claims describe omaveloxolone and a corticosteroid combination for cGVHD. This constitutes major, direct incompatibility with the provided FDA-approved prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Inqovi is a medication used for the treatment of chronic graft-versus-host disease (cGVHD) after at least two prior lines of systemic therapy.
The provided label excerpts for INQOVI list indications for MDS/CMML and AML (with venetoclax). cGVHD and prior-line requirements are not supported by the supplied label text.
Inqovi is a combination product that includes omaveloxolone and a corticosteroid.
The provided label description identifies INQOVI as decitabine and cedazuridine tablets; omaveloxolone and a corticosteroid are not described in the supplied label.
Omaveloxolone is a small molecule activator of the erythroid 2-related factor 2 (Nrf2) pathway.
The supplied label excerpts do not mention omaveloxolone or Nrf2.
Omaveloxolone targets the Nrf2 pathway.
The supplied label excerpts do not mention omaveloxolone or Nrf2.
The Nrf2 pathway plays a role in cellular protection against oxidative stress and inflammation.
The supplied label excerpts do not mention Nrf2 or oxidative stress/inflammation mechanism content.
By activating the Nrf2 pathway, omaveloxolone is thought to help reduce the inflammation and damage associated with chronic graft-versus-host disease.
The supplied label excerpts do not mention omaveloxolone, Nrf2, or any cGVHD mechanism.
Inqovi has received approval for the treatment of cGVHD.
The supplied label excerpts do not list cGVHD as an approved indication.
Contradictions
High
AI Statement
Inqovi is a combination product that includes omaveloxolone and a corticosteroid.
Label Reference
Label Section 11 (Description): INQOVI is decitabine and cedazuridine tablets (35 mg decitabine and 100 mg cedazuridine).
High
AI Statement
Inqovi is a medication used for the treatment of chronic graft-versus-host disease (cGVHD) after at least two prior lines of systemic therapy.
Label Reference
Label Section 1 (Indications and Usage): MDS/CMML and AML (with venetoclax); no cGVHD indication provided in the supplied excerpts.
Important Omissions
No mention of the actual labeled active ingredients (decitabine and cedazuridine), labeled indications (MDS/CMML and AML with venetoclax), or key labeled safety requirements (e.g., myelosuppression; embryo-fetal toxicity).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Claims describe an incorrect drug composition and an unapproved indication (cGVHD) relative to the provided INQOVI prescribing information, which could lead to inappropriate treatment decisions if acted upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple major mismatches with the supplied INQOVI label: incorrect indication (cGVHD) and incorrect composition/mechanism (omaveloxolone + corticosteroid) versus labeled decitabine/cedazuridine.
Suggested Improvement
Revise the response to match the supplied label: use INQOVI (decitabine/cedazuridine) indications for MDS/CMML and AML (with venetoclax), and remove omaveloxolone/corticosteroid/Nrf2/cGVHD claims unless corresponding FDA label text is provided.